

EQUITY IN ACCESS PROGRAM GOALS

ADVANCE UNDERSTANDING

of modifiable, underlying causes of inequitable access to care for blood cancer patients and survivors within the current healthcare system.

GENERATE ACTIONABLE EVIDENCE

to assist LLS in advocating for policies and developing programs that tangibly improve the lives of blood cancer patients and survivors.

IDENTIFY HEALTHCARE POLICIES AND PRACTICES

that have the potential to increase equitable access to cancer care and improve the quality of life and outcomes for blood cancer patients and survivors.

CULTIVATE HEALTH SERVICES RESEARCHERS

in the blood cancer space and contribute to LLS being recognized as a funding and thought leader in this area.

RESEARCH FUNDED

The Equity in Access Research Program has awarded more than \$12 million to health services researchers addressing critical issues such as the cost of oral anticancer medications, the role of health insurance in financial toxicity, and access to clinical trials.

In 2024 alone, the program awarded \$4.8 million to studies that will implement and evaluate interventions designed to improve therapeutic cancer clinical trial enrollment, particularly for underrepresented groups.



EQUITY IN ACCESS RESEARCH PROGRAM

The Leukemia & Lymphoma Society's (LLS) Equity in Access Research Program was created to generate new evidence to guide policy reform and enhancements to healthcare practice and program delivery that will mitigate the impact of social, economic, and environmental disadvantages and reduce barriers to care for individuals with a blood cancer.

LLS is the largest nonprofit funder of blood cancer research, investing nearly \$1.8 billion in the most pioneering science worldwide since 1949. We drive policy and regulatory changes that accelerate the development of new blood cancer treatments and break down barriers to care.

FUTURE OPPORTUNITIES

Scan here to view our funding opportunities and full list of grantees:

To connect with Equity in Access staff, email Senior Program Director, Dr. Eric Cooks at Eric.Cooks@LLS.org.



Support for this program provided by:
Royalty Pharma
AstraZeneca